- /
- Supported exchanges
- / US
- / THNR.US
Amplify Weight Loss Drug & Treatment ETF (THNR US) stock market data APIs
Amplify Weight Loss Drug & Treatment ETF Financial Data Overview
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Amplify Weight Loss Drug & Treatment ETF data using free add-ons & libraries
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
Get Amplify Weight Loss Drug & Treatment ETF End-of-day data
EOD Historical Data package for
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Amplify Weight Loss Drug & Treatment ETF News
New
FDA Clears NVO's Higher Dose of Wegovy: Diversify With These Health ETFs
The FDA recently approved higher-dose version of Novo Nordisk’s NVO obesity drug Wegovy, further expanding the drug giant’s footprint in the rapidly growing and fiercely competitive weight-loss m...
Healthcare ETFs to Watch as Novo Nordisk Tumbles on Poor Sales Outlook
Shares of Danish drugmaker Novo Nordisk NVO suffered a sharp slump of 15% on the bourses on Tuesday, after the company issued a conservative sales outlook that implied a 5-13% decline in 2026 from las...
The Obesity Pill Rush: Healthcare ETFs to Gain as FDA Nods to Novo Drug
The recent U.S. Food and Drug Administration (FDA) approval of Novo Nordisk’s NVO oral obesity pill, Wegovy, marks a significant turning point in the fiercely competitive weight-loss drug market. Th...
Eli Lilly Hits $1 Trillion Milestone: ETFs to Invest in
Eli Lilly LLY briefly crossed the $1 trillion market cap on Nov. 21, 2025 — becoming the first-ever health-care company to join the elite group mainly dominated by tech giants, as mentioned on CNBC....
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.